SCHEMBL4140263

SCHEMBL4140263

O=C(O)Cc1ccc(NC2=NC(=O)/C(=C/c3ccc4ccccc4c3)S2)cc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 6/20 0.47
NR1H4 Q96RI1 3/20 0.46
PTPN1 P18031 2/20 0.45
ACP1 P24666 2/20 0.45
AKR1B1 P15121 1/20 0.41
IKBKB O14920 1/20 0.40
PDE4B Q07343 1/20 0.39
PDE4D Q08499 1/20 0.39
S1PR4 O95977 1/20 0.39
S1PR5 Q9H228 1/20 0.39
DUSP3 P51452 1/20 0.39
DUSP22 Q9NRW4 1/20 0.39
MEN1 O00255 1/20 0.39
PIM1 P11309 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4140267 1.00 ALOX5 (0.47) ALOX5NR1H4PTPN1ACP1AKR1B1
SCHEMBL4137396 0.91 ALOX5 (0.38) ALOX5NR1H4PTPN1ACP1MEN1
SCHEMBL4137400 0.91 ALOX5 (0.38) ALOX5NR1H4PTPN1ACP1MEN1
SCHEMBL4635040 0.90 FFAR1 (0.49) ALOX5PTPN1ACP1AKR1B1MEN1
SCHEMBL4635037 0.90 FFAR1 (0.49) ALOX5PTPN1ACP1AKR1B1MEN1
SCHEMBL4133591 0.88 ALOX5 (0.50) ALOX5PDE4BPDE4DMEN1RAB9A
SCHEMBL4133593 0.88 ALOX5 (0.50) ALOX5PDE4BPDE4DMEN1RAB9A
SCHEMBL4133860 0.88 DUSP22 (0.49) ALOX5AKR1B1PDE4BDUSP3DUSP22
SCHEMBL4133862 0.88 DUSP22 (0.49) ALOX5AKR1B1PDE4BDUSP3DUSP22
SCHEMBL4134117 0.87 PTPN22 (0.51) ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP disclosed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ ALOX5 3505/4885NR1H4 2884/4885PTPN1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.